Best CAR-T CDMOs in United States

Last updated: 2026-10-20 · updated as new inspection, certificate, and trial data enters the platform

← All CAR-T CDMOs Best Clean FDA History Commercial Scale

Region: USA Europe Asia UK India Switzerland Germany South Korea Japan China

CDMOs tracked

Fully scored

With FDA records

FDA inspections

EMA/MHRA GMP certs

For US-manufactured car-t programs, Bristol Myers Squibb (CGT Mfg), City of Hope (T Cell Manufacturing), and Novartis Contract Manufacturing lead CDMO Signal's ranking of car-t CDMOs with confirmed US facilities. Filtered from the global directory of 31 scored car-t CDMOs to 4 with US manufacturing presence. US-based manufacturing carries specific advantages for sponsors filing under FDA jurisdiction: FDA inspection records — which form the core of the Signal Score's Quality Compliance pillar — apply directly, and QP release complexity common to EU-manufactured material does not apply. Rankings update as new inspection and certificate data enters the platform. Full methodology at cdmosignal.com/methodology.

CAR-T CDMOs manufacture engineered T-cell products, combining viral-vector transduction, T-cell activation and expansion, and rapid release testing — usually as autologous, per-patient batches on tight vein-to-vein timelines.

Choosing a CAR-T CDMO depends on autologous vs allogeneic experience, in-house vs sourced vector, closed-system processing, and chain-of-identity logistics, alongside a clean regulatory record. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.

FDA inspection outcomes across these CDMOs: 15 NAI (no action), 15 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: United States (25), Denmark (23), Germany (7), France (4), Ireland (4).

Last updated 2026-10-20. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

#	CDMO	Signal Score	Quality	FDA · GMP	Capacity	Programs
1	BMS Bristol Myers Squibb (CGT Mfg) Bothell, WA · Warren, NJ	87.0	97.2	8 insp · 2 GMP	—	585 programs
2	COH City of Hope (T Cell Manufacturing) Duarte, CA	83.9	97.2	3 insp · 0 GMP	—	213 programs
3	NV Novartis Contract Manufacturing Morris Plains, NJ · Stein, CH	81.3	97.2	2 insp · 0 GMP	Constrained	284 programs
4	AG AGC Biologics Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP Hiring · 35 open roles	78.5	99.8	4 insp · 27 GMP	Available	2 programs
5	CR Charles River Laboratories Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD	86.3	99.2	9 insp · 11 GMP	Limited	0 programs
6	MN Minaris Advanced Therapies Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP	83.0	99.1	3 insp · 4 GMP	Limited	0 programs
7	RC RoslinCT Edinburgh, UK · Hopkinton, MA Hiring · 10 open roles	79.3	96.7	1 insp · 1 GMP	Available	0 programs
8	FH Fred Hutch Cell Therapy Lab Seattle, WA	76.3	—	—	—	454 programs
9	PBI ProBio Pennington, NJ · Nanjing, CN	64.0	—	—	—	0 programs
10	VE Rose BioSolutions Rockville, MD · Memphis, TN · Keele, United Kingdom	63.0	—	—	—	0 programs
11	CT CTMC Houston, TX	63.0	—	—	—	0 programs
12	CL Cellares South San Francisco, CA Hiring · 1 open role	59.0	—	—	Available	0 programs
13	MS Made Scientific Princeton, NJ	59.0	—	—	—	0 programs
14	EB ElevateBio BaseCamp Waltham, MA Hiring · 11 open roles	59.0	—	—	—	0 programs
15	MX MaxCyte Gaithersburg, MD	59.0	—	—	—	0 programs
16	AS Artis BioSolutions Lake Nona, FL Hiring · 9 open roles	59.0	—	—	—	0 programs
17	PO Poseida Therapeutics (CDMO) San Diego, CA Hiring · 3 open roles	58.7	—	—	—	6 programs

How we score CDMOs →

What to evaluate in a CAR-T CDMO

Vector supply

CAR-T needs a lentiviral or retroviral vector. Confirm whether the CDMO produces vector in-house or coordinates a supplier, and how that affects timelines and cost.

Autologous logistics & turnaround

Autologous CAR-T lives or dies on vein-to-vein time and chain-of-identity. Evaluate scheduling, apheresis handling, and cryo-logistics.

Closed, scalable processing

Closed and automated platforms reduce contamination risk and support parallel patient slots. Ask about cleanroom grade and concurrent-batch capacity.

Regulatory track record

Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.

FDA jurisdiction — how the ranking scores US-based CDMOs

The Signal Score's Quality Compliance pillar (35% of the composite) is dominated by FDA inspection data for US-based CDMOs: Establishment Inspection Report classifications (NAI, VAI, OAI), Form 483 observation counts, and Warning Letter history. For a CDMO whose primary facility footprint is US, this pillar carries direct weight — an inspection on the site slated for a sponsor's program applies without translation. For CDMOs with mixed US + international facility footprint, the ranking reflects the composite regulatory posture; sponsors evaluating for a specific program should verify inspection history on the exact US site under consideration via that CDMO's profile page.

Which US CDMOs also cover EU and UK regulatory geographies?

Many top-tier US-based CDMOs maintain EU (EMA) and UK (MHRA) GMP certification for facilities used to supply EU and UK trials or commercial markets. The Signal Score's Quality Compliance pillar includes EMA + MHRA certificate density as a component — a US-headquartered CDMO with dense EU/UK certificates typically ranks higher on this pillar than a US-only competitor. Sponsors running dual-jurisdiction programs should cross-check the individual CDMO profile pages for specific certificate coverage; the Europe region ranking surfaces CDMOs that also appear in the European jurisdiction ranking, indicating multi-region regulatory posture.

How CDMO Signal identifies US manufacturing presence

Region attribution is derived from each CDMO's declared facility locations in our directory. A CDMO's facility list is validated against corporate filings, press releases, and — where public — the FDA facility registration (FEI number lookups). Region matching is done at the country level: a US state name or two-letter abbreviation in the facility list places the CDMO in the US region. CDMOs with US + international sites appear in every applicable region ranking, which reflects operational reality — such a CDMO is a legitimate candidate for programs in any of those jurisdictions.

CAR-T CDMOs — Frequently Asked Questions

Who are the top CAR-T CDMOs?

By CDMO Signal's independent Signal Score, the top-ranked CAR-T CDMOs include Bristol Myers Squibb (CGT Mfg), City of Hope (T Cell Manufacturing), Novartis Contract Manufacturing. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.

How many CAR-T CDMOs have FDA inspection records?

CDMO Signal tracks 7 CAR-T CDMOs with FDA inspection records and 45 EMA/MHRA GMP certificates across the group.

What should I look for in a CAR-T CDMO?

Confirm vector supply (in-house or coordinated), autologous logistics and vein-to-vein turnaround, closed-system scalable processing for parallel patients, and a clean FDA and EMA/MHRA record.

Do CAR-T CDMOs make their own viral vectors?

Some produce lentiviral or retroviral vector in-house; others coordinate an external vector CDMO. In-house vector can shorten timelines and de-risk supply. Check each profile's modality coverage above.

Compare side-by-side

See two CDMOs' scoring, inspection history, and clinical footprint next to each other.

Open comparison →

Run a sourcing search

Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.

Search for a CDMO →

Save this CAR-T shortlist

Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.

Related modalities

Cell Therapy CDMOs Lentiviral Vector CDMOs Gene Editing CDMOs

Other Modalities

AAV Lentiviral Cell Therapy mRNA/LNP Plasmid DNA Biologics Oligo/ASO Adenoviral Gene Editing Exosome Recombinant Proteins ADC Gene Therapy Cell & Gene Therapy Viral Vector